Johns Hopkins ABX Guide
Cefepime
INDICATIONS
FDA
FDA
- Pneumonia caused by S. pneumoniae
- Including cases associated with concurrent bacteremia, P. aeruginosa, K. pneumoniaeor Enterobacter species.
- Febrile neutropenia (empiric therapy)
- Uncomplicated and complicated urinary tract infections, including pyelonephritis (+/- bacteremia) caused by E. coli, K. pneumoniae, or P. mirabilis
- Uncomplicated skin and skin-structure infections caused by MSSA or S. pyogenes.
- Complicated intra-abdominal infections (combined with metronidazole) caused by E. coli, viridans group streptococci, P. aeruginosa, K. pneumoniae, Enterobacter species, or B. fragilis.
- Active against most isolates of the following microorganisms (in vitro and clinical infections)
- Aerobic Gram-Positive Microorganisms:
- Staphylococcus epidermidis (methicillin-susceptible isolates only)
- Staphylococcus saprophyticus
- Streptococcus agalactiae (Lancefield’s Group B streptococci)
- Aerobic Gram-Negative Microorganisms:
- Acinetobacter calcoaceticus subsp. lwoffii
- Citrobacter diversus
- Citrobacter freundii
- Enterobacter agglomerans
- Haemophilus influenzae (including beta-lactamase-producing isolates)
- Hafnia alvei
- Klebsiella oxytoca
- Moraxella catarrhalis (including beta-lactamase-producing isolates)
- Morganella morganii
- Proteus vulgaris
- Providencia rettgeri
- Providencia stuartii
- Serratia marcescens
- Aerobic Gram-Positive Microorganisms:
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Shunt infections, CNS
- Appendicitis (with metronidazole)
- Diverticulitis (with metronidazole)
- Intra-abdominal abscess (with metronidazole)
- Osteomyelitis, acute
- Osteomyelitis, chronic
- Diabetic foot infection (with metronidazole or clindamycin)
- Hardware-associated septic arthritis
- Acute exacerbations of chronic bronchitis
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 6, 2023
Citation
Auwaerter, Paul G, and Kathryn Dzintars. "Cefepime." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540090/2/Cefepime.
Auwaerter PG, Dzintars K. Cefepime. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540090/2/Cefepime. Accessed December 28, 2024.
Auwaerter, P. G., & Dzintars, K. (2023). Cefepime. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540090/2/Cefepime
Auwaerter PG, Dzintars K. Cefepime [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 December 28]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540090/2/Cefepime.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Cefepime
ID - 540090
A1 - Auwaerter,Paul,M.D.
AU - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2023/10/06/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540090/2/Cefepime
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
